These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27846415)

  • 21. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
    Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.
    Saunders KO; Nicely NI; Wiehe K; Bonsignori M; Meyerhoff RR; Parks R; Walkowicz WE; Aussedat B; Wu NR; Cai F; Vohra Y; Park PK; Eaton A; Go EP; Sutherland LL; Scearce RM; Barouch DH; Zhang R; Von Holle T; Overman RG; Anasti K; Sanders RW; Moody MA; Kepler TB; Korber B; Desaire H; Santra S; Letvin NL; Nabel GJ; Montefiori DC; Tomaras GD; Liao HX; Alam SM; Danishefsky SJ; Haynes BF
    Cell Rep; 2017 Feb; 18(9):2175-2188. PubMed ID: 28249163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth.
    Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M
    J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
    Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
    J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.
    Sok D; Pauthner M; Briney B; Lee JH; Saye-Francisco KL; Hsueh J; Ramos A; Le KM; Jones M; Jardine JG; Bastidas R; Sarkar A; Liang CH; Shivatare SS; Wu CY; Schief WR; Wong CH; Wilson IA; Ward AB; Zhu J; Poignard P; Burton DR
    Immunity; 2016 Jul; 45(1):31-45. PubMed ID: 27438765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.
    Andrabi R; Su CY; Liang CH; Shivatare SS; Briney B; Voss JE; Nawazi SK; Wu CY; Wong CH; Burton DR
    Immunity; 2017 Sep; 47(3):524-537.e3. PubMed ID: 28916265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
    Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
    Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
    Cohen YZ; Lavine CL; Miller CA; Garrity J; Carey BR; Seaman MS
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1192-201. PubMed ID: 26149894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.
    Panico M; Bouché L; Binet D; O'Connor MJ; Rahman D; Pang PC; Canis K; North SJ; Desrosiers RC; Chertova E; Keele BF; Bess JW; Lifson JD; Haslam SM; Dell A; Morris HR
    Sci Rep; 2016 Sep; 6():32956. PubMed ID: 27604319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.
    Duenas-Decamp MJ; Clapham PR
    J Virol; 2010 Sep; 84(18):9608-12. PubMed ID: 20610714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies.
    van den Kerkhof TL; van Gils MJ; Boeser-Nunnink BD; Burger JA; Schuitemaker H; Sanders RW
    AIDS; 2016 Sep; 30(14):2179-84. PubMed ID: 27258397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
    Yang Q; Li C; Wei Y; Huang W; Wang LX
    Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.
    Moore PL; Gray ES; Wibmer CK; Bhiman JN; Nonyane M; Sheward DJ; Hermanus T; Bajimaya S; Tumba NL; Abrahams MR; Lambson BE; Ranchobe N; Ping L; Ngandu N; Abdool Karim Q; Abdool Karim SS; Swanstrom RI; Seaman MS; Williamson C; Morris L
    Nat Med; 2012 Nov; 18(11):1688-92. PubMed ID: 23086475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
    Doores KJ; Burton DR
    J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.